CL2017000244A1 - Formulaciones de compuestos biológicos para instilación intravesical. - Google Patents

Formulaciones de compuestos biológicos para instilación intravesical.

Info

Publication number
CL2017000244A1
CL2017000244A1 CL2017000244A CL2017000244A CL2017000244A1 CL 2017000244 A1 CL2017000244 A1 CL 2017000244A1 CL 2017000244 A CL2017000244 A CL 2017000244A CL 2017000244 A CL2017000244 A CL 2017000244A CL 2017000244 A1 CL2017000244 A1 CL 2017000244A1
Authority
CL
Chile
Prior art keywords
formulations
biological compounds
intravesical instillation
intravesical
instillation
Prior art date
Application number
CL2017000244A
Other languages
English (en)
Inventor
Patrick M Hughes
Eric A Forssen
David C Rupp
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2017000244A1 publication Critical patent/CL2017000244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Abstract

<p>SE DESCRIBEN FORMULACIONES FARMACÉUTICAS QUE COMPRENDEN UN DERIVADO CLOSTRIDIAL Y UN AGENTE PERMEABILIZANTE PARA INSTALACIÓN INTRAVESICAL.</p>
CL2017000244A 2014-07-31 2017-01-30 Formulaciones de compuestos biológicos para instilación intravesical. CL2017000244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462031302P 2014-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
CL2017000244A1 true CL2017000244A1 (es) 2017-10-13

Family

ID=53801236

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000244A CL2017000244A1 (es) 2014-07-31 2017-01-30 Formulaciones de compuestos biológicos para instilación intravesical.

Country Status (17)

Country Link
US (2) US20160030570A1 (es)
EP (2) EP3174523B1 (es)
JP (3) JP6585157B2 (es)
KR (2) KR20220048046A (es)
CN (1) CN106573041A (es)
AU (2) AU2015296256A1 (es)
BR (1) BR112017001888A2 (es)
CA (1) CA2955492A1 (es)
CL (1) CL2017000244A1 (es)
CO (1) CO2017001712A2 (es)
DK (1) DK3174523T3 (es)
ES (1) ES2821731T3 (es)
IL (1) IL250086B (es)
PH (1) PH12017500178A1 (es)
RU (2) RU2020115111A (es)
SG (1) SG11201700736YA (es)
WO (1) WO2016019180A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
RU2743805C1 (ru) * 2020-06-26 2021-02-26 Государственное бюджетное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Уральский институт травматологии и ортопедии имени В.Д. Чаклина" (ГБУЗ СО "ЦСВМП "УИТО им. В.Д. Чаклина") Способ лечения нейрогенного мочевого пузыря
RU2751649C1 (ru) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Способ лечения и профилактики цистита
WO2022214964A2 (en) * 2021-04-06 2022-10-13 Connectomica Spa. Selective connexin hemichannel blockers as therapeutic compounds and methods for treating inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
KR100876060B1 (ko) 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP4981280B2 (ja) 2005-08-23 2012-07-18 本田技研工業株式会社 燃料電池
JP2009543557A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力およびクロストリジウム毒素標的細胞に対する変化したターゲティング活性を有する改変クロストリジウム毒素
BR122012027456A2 (pt) 2008-03-14 2015-07-14 Allergan Inc Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2373294B1 (en) * 2008-12-10 2016-04-20 Allergan, Inc. Clostridial toxin pharmaceutical compositions
BRPI0923731B1 (pt) * 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
KR20200146046A (ko) 2009-03-13 2020-12-31 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
US8455203B2 (en) 2009-03-13 2013-06-04 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
MX2012006985A (es) 2009-12-16 2012-09-12 Allergan Inc Toxinas clostridium modificadas que comprenden un dominio de enlace al sitio de escision de la proteasa integrado.
US10471150B2 (en) * 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
JP6148979B2 (ja) 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
ES2821098T3 (es) * 2012-04-08 2021-04-23 Urogen Pharma Ltd Preparaciones de hidrogel térmico reversible para su uso en el tratamiento de trastornos del urotelio
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US11182864B1 (en) 2015-07-13 2021-11-23 David C. Fox Non-sequential restaurant order system and method

Also Published As

Publication number Publication date
JP2017522344A (ja) 2017-08-10
RU2017103978A3 (es) 2019-01-24
CA2955492A1 (en) 2016-02-04
US20160030570A1 (en) 2016-02-04
AU2020250260A1 (en) 2020-11-05
AU2015296256A1 (en) 2017-03-02
CN106573041A (zh) 2017-04-19
CO2017001712A2 (es) 2017-05-19
BR112017001888A2 (pt) 2017-11-28
EP3174523B1 (en) 2020-07-01
US20230256097A1 (en) 2023-08-17
EP3747427A1 (en) 2020-12-09
ES2821731T3 (es) 2021-04-27
SG11201700736YA (en) 2017-02-27
JP2020055798A (ja) 2020-04-09
EP3174523A1 (en) 2017-06-07
DK3174523T3 (da) 2020-09-28
IL250086B (en) 2020-11-30
IL250086A0 (en) 2017-03-30
RU2017103978A (ru) 2018-08-28
WO2016019180A1 (en) 2016-02-04
KR20220048046A (ko) 2022-04-19
KR20170038030A (ko) 2017-04-05
PH12017500178A1 (en) 2017-06-28
RU2020115111A (ru) 2020-06-10
JP6585157B2 (ja) 2019-10-02
RU2720991C2 (ru) 2020-05-15
JP2022081521A (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO2017001994A2 (es) Compuestos activos hacia bromodominios
GT201600249A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
BR112018072663A2 (pt) moduladores da via integrada ao estresse
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016002784A1 (es) Emulsión de agua en aceite para el cuidado de la piel
BR112016025470A2 (pt) ?hdl terapêutico?
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DK3137053T3 (da) Formuleringer af biologiske lægemidler til intravesikal instillation
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2017000244A1 (es) Formulaciones de compuestos biológicos para instilación intravesical.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2016002779A1 (es) Composición para el cuidado de la piel
GT201600252A (es) Derivados de naftiridinadiona
PE20170702A1 (es) Derivados estabilizados de adrenomedulina y uso de los mismos